Image Place holder

Shohreh Dickinson, MD

 
Specialty: Pathology
Sub Specialty: Pediatric Pathology
Program: Pathology

Overview

Cancer Focus: Adrenal Carcinoma, Bladder Cancer, Kidney (Renal Cell) Cancer, Prostate Cancer, Testicular Cancer

Shohreh Dickinson serves in the Genitourinary Oncology program at H. Lee Moffitt Cancer Center and Research Institute (MCC) with role primarily focused on clinical service, teaching and research.  Her education includes a B.S. in Chemistry from Stetson University, an M.D. in 1992 from the University of South Carolina School of Medicine in Columbia, South Carolina, and a five year residency in Anatomic and Clinical Pathology in 1997 at the University of South Florida (USF) Affiliated Hospitals in Tampa, Florida.  This was followed by completion of a fellowship in Hematopathology in 1998 at the University of Michigan in Ann Arbor, Michigan.  In April of 2007, I accepted a position as assistant member at Moffitt Cancer Center where she was appointed assistant professor in the Department of Oncologic Sciences in the College of Medicine at the USF. 


Education & Training

Fellowship:

  • University of Michigan - Hematopathology

Residency:

  • University of South Florida Affiliated Hospitals - Anatomic & Clinical Pathology

Medical School:

  • University of South Carolina School of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
  • Di Pietro G, Luu HN, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY. Biomarkers and new therapeutic targets in renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018 Sep.22(18):5874-5891. Pubmedid: 30280768.
  • Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec.9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
  • Jeong JH, Dickinson SI, Luo JL. Targeting constitutive NF-κB specifically in tumor cells. Oncotarget. 2017 Nov.8(55):93305-93306. Pubmedid: 29212145. Pmcid: PMC5706791.
  • Al Diffalha S, Al Aukla N, Hasan S, Dickinson S, Khalil F. NUT Midline Carcinoma: A Rare Malignancy. Cancer Control. 2017 Apr.24(2):202-206. Pubmedid: 28441376.
  • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
  • Wu M, Dickinson SI, Wang X, Zhang J. Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2014 Sep.7(10):6504-6513. Pubmedid: 25400728. Pmcid: PMC4230126.
  • Velez-Cubian F, Gabordi R, Smith P, Dickinson S, Moodie C, Garrett J, Toloza E. Delayed Presentation of Breast Cancer Metastatic to Solitary Fibrous Tumor of the Lung With Synchronous Contralateral Primary Non-small Cell Lung Cancer: A Case Report. Chest. 2014 Mar.145(3 Suppl):295A. Pubmedid: 24638457.
  • Russell CM, Buethe DD, Dickinson S, Sexton WJ. Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. Ann Clin Lab Sci. 2014 Dec.44(1):91-98. Pubmedid: 24695481.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar.2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec.110(11 Pt B):E475-E480. Pubmedid: 22564727.
  • Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dickinson SI, Kang LC. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010 Oct.17(4):256-268. Pubmedid: 20861813.
  • Dickinson SI. Premalignant and malignant prostate lesions: pathologic review. Cancer Control. 2010 Oct.17(4):214-222. Pubmedid: 20861809.
  • Iravani S, Zhang HQ, Yuan ZQ, Cheng JQ, Karl RC, Jove R, Coppola D. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol. 2003 Oct.34(10):975-982. Pubmedid: 14608530.
  • Miranda E, Iravani S, Doll D. Unusual presentations of malignancy. Case 2. Breast plasmacytoma in a patient with human immunodeficiency virus. J Clin Oncol. 2001 Jul.19(13):3290-3291. Pubmedid: 11432898.
  • Babbin BA, Greene JN, Vega R, Iravani S, Ku NN, Sandin RL. Pathologic manifestations of invasive pulmonary aspergillosis in cancer patients: the many faces of aspergillus. Cancer Control. 2000 Nov.7(6):566-571. Pubmedid: 11088066.
  • Iravani S, Debich-Spicer D, Gilbert-Barness E. Pathological case of the month. Campomelic dysplasia. Arch Pediatr Adolesc Med. 2000 Jul.154(7):747-748. Pubmedid: 10891031.
  • Iravani S, Singleton T, Ross C, Schnitzer B. Precursor B lymphoblastic lymphoma presenting as lytic bone lesions. Am J Clin Pathol. 1999 Dec.112(6):836-843. Pubmedid: 10587707.
  • Iravani S, Mao W, Fu L, Karl R, Yeatman T, Jove R, Coppola D. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest. 1998 Mar.78(3):365-371. Pubmedid: 9520949 .
  • Iravani S, Mora L, Miller F, Dawson P. Altered expression of c-erbB-2, DF3, b72.3, p53 and Ki-67 with progression and differentiation to two distinct histologic types of invasive carcinoma in the MCF10AT human xenograft model of proliferative breast disease. Int J Oncol. 1998 Feb.12(2):369-375. Pubmedid: 9458364 .
  • Iravani S, Bower R, Debich-Spicer D, Gilbert-Barness E. Pathological case of the month. Bronchopulmonary sequestration, intralobar type. Arch Pediatr Adolesc Med. 1997 Oct.151(10):1059-1060. Pubmedid: 9343023 .
  • Iravani S, Walling A, Gilbert-Barness E. Pathological case of the month. Adamantinoma. Arch Pediatr Adolesc Med. 1997 Apr.151(4):427-428. Pubmedid: 9111446 .

Patient Comments
Overall Satisfaction
0

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments